Removing doubt: Implantable ST-segment monitor can eliminate delay in MI treatment

May 6, 2010 | Reed Miller From

San Diego, CA – An intracardiac ST-segment monitor, which alerts patients to significant ST shifts indicative of thrombotic occlusion, reduced patients’ “alarm-to-hospital” time from the typical two to three hours to less than 20 minutes in early studies.

Results of the first two pilot studies of the AngelMed Guardian implantable ischemia detection system (Angel Medical Systems, Shrewsbury, NJ) were presented as a poster here at the Society for Cardiovascular Angiography and Interventions (SCAI) 2010 Scientific Sessions by Dr David Holmes (Mayo Clinic, Rochester, MN), who said that the results will also soon be published. Angel Medical sponsored the studies. Continue reading

Blood test identifies people at risk for heart attack that other tests miss

ScienceDaily (Apr. 20, 2010) — A simple blood test can identify people who are at risk for a heart attack, including thousands who don’t have high cholesterol, according to researchers at Oregon Health & Science University.

The new test measures gamma-prime fibrinogen, a component of the blood’s clotting mechanism. Elevated levels indicate greater likelihood of a heart attack, even when other signs don’t point to cardiovascular trouble, says David H. Farrell, Ph.D., professor of pathology in the OHSU School of Medicine and a member of OHSU’s Heart Research Center. The results were recently published in Clinical Chemistry.

Continue reading

Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes

ScienceDaily (2010-03-30) — Researchers have gathered evidence that dangerous plaques in blood vessels can rupture by overproducing protein-digesting enzymes. Such ruptures can lead to artery-blocking clots. Almost everyone over age 60 has arterial plaque. Ruptures are what convert atherosclerosis from an indolent disease to a life-threatening emergency. The findings suggest ideas for diagnosing vulnerable plaques and developing new approaches to preventing and treating heart attacks and strokes by decreasing production of protein-destroying enzymes in vulnerable plaques or blocking their actions.

To read further: